Severe microcirculatory dysfunction is associated with multiple organ injury and mortality in patients with septic shock \[[@CR1]--[@CR3]\]. Microcirculatory dysfunction includes endothelial damage, impaired vasoregulation, and coagulation activation \[[@CR4], [@CR5]\], and this dysfunction may present as capillary leakage, hypotension, microthrombosis and impair the tissue perfusion. One of the leading causes of microcirculatory dysfunction is endotoxin, which can induce excessive immune reactions, inflammatory responses, and oxidative stress \[[@CR6]\]. Endotoxin injury can be reduced by antagonization or removal strategy. A Toll-like receptor 4 antagonist was reported to improve microcirculation in endotoxemic rats \[[@CR7]\]. Moreover, direct hemoperfusion with a polymyxin B-immobilized column was determined to be effective to reduce circulating endotoxins \[[@CR8]\]. A rat sepsis model revealed that removal of circulating endotoxin using polymyxin-B hemoperfusion (PMX-HP) can maintain a better microcirculation and lower damage markers \[[@CR9]\]. Notably, poor microcirculation parameters reflect inadequate tissue perfusion \[[@CR10], [@CR11]\]; thus, the improvement of microcirculation may ensure adequate tissue perfusion and prevent ischemic damage of organs. To the best of our knowledge, no clinical study has investigated the effect of PMX-HP treatment on microcirculation in patients with septic shock. Therefore, we hypothesized that PMX-HP treatment can improve microcirculation by removing endotoxin and reducing endotoxin-related microcirculatory dysfunction. The primary aim of this study was to investigate the effects of PMX-HP on microcirculation in patients with septic shock.

Methods {#Sec1}
=======

Study design and patient selection {#Sec2}
----------------------------------

This prospective, randomized, controlled study was approved by the Research Ethics Committee of National Taiwan University Hospital (approval number: 201208067RIB) and registered on the ClinicalTrials.gov protocol registration system (ID: NCT01756755). This study was conducted between October 2013 and July 2018. The definition of sepsis and septic shock met the criteria of international consensus definition \[[@CR12], [@CR13]\]. Inclusion criteria for patients with septic shock were intra-abdominal infection with adequate management, proven gram-negative bacteria infection, or endotoxin activity assay (EAA) level of \> 0.6 EAA units in patients with pneumonia, blood stream infection, or urinary tract infection. Exclusion criteria were age less than 20 years, the onset of sepsis and septic shock more than 24 h at enrollment, pregnancy, participation in interventional trials at other intensive care units (ICUs) within 30 days before enrollment, undergoing organ transplant surgery within 1 year before enrollment, life-expectancy less than 30 days, history of cardiopulmonary resuscitation (CPR) within 30 days before enrollment, signed no-CPR consent before enrollment, hemophilia, allergic history to polymyxin B or heparin, uncontrolled bleeding within 24 h before enrollment, renal replacement therapy before enrollment, white blood cells count less than 0.5 K/uL or platelet count less than 50 K/uL, human immunodeficiency virus infection, Acute Physiology and Chronic Health Evaluation (APACHE) II score higher than 30 at enrollment, and non-native speakers. Moreover, patients were not enrolled if they declined to participate. Informed consent was obtained from patients' legally authorized representatives before enrollment. After enrollment, patients were randomly assigned to the control and PMX-HP groups based on the opaque, sealed envelope technique. In the control group, septic shock was treated according to the practice guidelines for sepsis and septic shock \[[@CR13], [@CR14]\]. In the PMX-HP group, patients received one session of PMX-HP within 24 h after the onset of septic shock in addition to conventional septic shock management. Sublingual microcirculation video sequences were recorded using a sidestream dark field video microscope (MicroScan; Microvision Medical, Netherlands) at the following time points: T0, enrollment; T1, 24--26 h after T0; and T2, 48 h after T0. At T1, patients in the PMX-HP group received a second session of PMX-HP if the patient's septic shock was not resolved. At each time point, clinical data, mean arterial pressure (MAP), norepinephrine infusion dose, APACHE II score, sequential organ failure assessment (SOFA) score, laboratory data, the length of ICU and hospital stay, and survival status at 28 days were recorded. Arterial oxygen tension/fraction of inspired oxygen concentration (PaO~2~/FiO~2~) ratio was recorded if the data were available.

PMX-HP treatment protocol {#Sec3}
-------------------------

PMX-HP was performed using an extracorporeal hemoperfusion cartridge with polymyxin B immobilized on polystyrene fibers (Toraymyxin PMX-20R, Toray Industries, Tokyo, Japan). Cartridge and circuit were first washed using 4 L 0.9% saline and then primed with 4000 IU heparin in 1 L 0.9% saline. Vascular access was obtained using double-lumen venous catheter. The blood was perfused at a flow rate of 100 to 150 mL/min for 2 h. During PMX-HP treatment, patients received heparin at a loading dose of 3000 IU and a maintenance dose of 20 U/kg/h following manufacturer's instruction. Notably, the heparin dose was adjusted according to our heparin dosing score protocol in patients with coagulopathy to avoid any bleeding event \[[@CR15]\].

Measurements of sublingual microcirculation {#Sec4}
-------------------------------------------

Five video sequences (length: 20 s each) were recorded at different sites on ventral aspect of the tongue according to the consensus guidelines \[[@CR16]\] by one of the two operators, a clinical research nurse (Ms. Wang) and Dr. Yeh, who had been trained and taken more than 300 and 100, respectively, microcirculation recordings for patients and health volunteers. These video sequences were digitally stored with code numbers to ensure the anonymity of patient information. Subsequent microcirculation analyses were performed according to the consensus guidelines \[[@CR16]\] by a research assistant (Ms. Wu, who had been trained and analyzed more than 3000 video sequences of animal and human microcirculation) who was blinded to the patient information. Three sequences with appropriate image quality were selected for analysis using the semi-automated analysis software Automated Vascular Analysis 3.0 \[[@CR17]\]. Inappropriate image quality included pressure or secretion artifact, and inadequate focus and contrast adjustments \[[@CR17]\]. The following parameters were investigated: (a) total vessel density (TVD; vessels less than 20 μm), (b) perfused vessel density (PVD), (c) proportion of perfused vessels (PPV), and (d) microvascular flow index (MFI) score. TVD was automatically calculated by the software. The blood flow in small vessels was classified using an ordinal scale of 0--3, and small vessels with a blood flow classification of 2 or 3 were considered as perfused vessels \[[@CR18]\]. PVD was semi-automatically calculated by the software. The MFI scores were semiquantitatively calculated according to suggestions made at the roundtable conference \[[@CR19]\].

End points and sample size analysis {#Sec5}
-----------------------------------

The primary end point was the difference in PVD between the control and PMX-HP groups at T2. Based on our experience, 20 patients per group were sufficient to detect a 12% difference of PVD between the two groups, with an α level of 0.05 (two-tailed) and a β level of 0.2, assuming a controlled mean PVD of 20.0 mm/mm^2^ with a standard deviation of 3.0. The secondary end points included the difference in APACHE II score, SOFA score, and MAP between the two groups at T2.

Statistical analysis {#Sec6}
--------------------

All statistical analyses were performed using SPSS version 20 (IBM, Armonk, NY, USA). Normally distributed numerical data were expressed as means (standard deviation) and compared using *t* test. Non-normal distributed numerical data, TVD, and PVD were expressed as medians (interquartile range) and compared using the Mann--Whitney test. Categorical variables were described as percentages and were compared using the Chi-square test or Fisher's exact test as appropriate. Intention-to-treat analysis was used for most comparisons between the two groups. Intention-to-treat, as-treated, and per-protocol analysis were used to investigate the difference in PVD between the two groups. A *p* value of \< 0.05 was considered statistically significant.

Results {#Sec7}
=======

Patient characteristics {#Sec8}
-----------------------

A total of 223 patients with severe sepsis and septic shock were initially considered for inclusion in this trial (Fig. [1](#Fig1){ref-type="fig"}). Subsequently, 194 patients were excluded, and 29 patients were randomized. However, in the PMX-HP group, one patient signed no CPR consent and decided to pursue palliative care after enrollment. Therefore, finally, 28 patients were analyzed. In the PMX-HP group, 10 patients received one session of PMX-HP, and 4 patients received two sessions of PMX-HP. In the control group, one patient requested self-financed PMX-HP and received one session of PMX-HP. Patient characteristics are listed in Table [1](#Tab1){ref-type="table"}. Patients' characteristics did not differ significantly between the control and PMX-HP groups.Fig. 1Consort flowchart of patient enrollment. *APACHE* acute physiology and chronic health evaluation, *CPR* cardiopulmonary resuscitation, *PMX*-*HP* polymyxin B hemoperfusionTable 1Patient characteristics, hemodynamic and laboratory data, and treatments for septic shockGroupControlPMX-HP*p* valuesNumber of patients1414Age (in years)68.2 (14.3)67.7 (10.8)0.920Female, *n* (%)7 (50%)8 (57%)1.000Height (cm)158 (9)162 (13)0.368Weight (kg)62.7 (12.2)64.7 (17.5)0.723APACHE II score19 (6)19 (5)0.973At T0 SOFA score9 (3)9 (2)0.890 Intra-abdominal infection, *n* (%)13 (93%)13 (93%)1.000 WBC count (k/μL)12.5 (5.2--37.6)14.9 (6.5--27.5)0.603 Hemoglobin (g/dL)11.1 (1.7)12.0 (2.4)0.292 Body temperature (°C)37.3 (1.0)38.0 (1.0)0.071 Heart rate (bpm)109 (22)111 (17)0.843 MAP (mmHg)76 (10)75 (7)0.709 Lactate (mmol/L)4.1 (3.4)4.0 (3.3)0.940 Norepinephrine (mcg/kg/min)0.11 (0.05--0.17)0.20 (0.13--0.28)0.056At T1 SOFA score7 (4)7 (4)0.919 WBC count (k/μL)18.1 (7.1--35.8)16.3 (9.8--20.9)0.344 Hemoglobin (g/dL)9.5 (1.5)9.7 (1.5)0.749 Body temperature (°C)36.7 (1.0)36.9 (0.6)0.434 Heart rate (bpm)90 (10)96 (21)0.346 MAP (mmHg)84 (11)83 (11)0.764 Lactate (mmol/L)2.5 (1.4)2.3 (1.2)0.688 Norepinephrine (mcg/kg/min)0.01 (0--0.03)0.01 (0--0.06)0.511 Fluid supplement (0--24 h) (mL)3639 (3056--4177)3811 (2652--4908)0.874At T2 SOFA score6 (4)6 (4)0.877 WBC count (k/μL)14.6 (12.0--21.3)17.6 (13.6--22.3)0.525 Hemoglobin (g/dL)9.8 (1.2)9.4 (1.3)0.503 Body temperature (°C)36.6 (0.7)37.1 (1.1)0.157 Heart rate (bpm)90 (19)87 (19)0.647 MAP (mm Hg)86 (13)83 (13)0.518 Lactate (mmol/L)1.4 (0.8)1.8 (0.8)0.354 Norepinephrine (mcg/kg/min)0 (0--0)0 (0--0.01)0.657 Fluid supplement (25--48 h) (mL)2452 (1762--3101)2339 (1773--3190)1.000Data are presented as the mean (SD) for normal distribution data or median (interquartile range) for non-normal distribution data*APACHE* acute physiology and chronic health evaluation, *MAP* mean arterial pressure, *PMX*-*HP* polymyxin B hemoperfusion, *SOFA* sequential organ failure assessment, *WBC* white blood cells

Hemodynamic parameters, laboratory data, and clinical outcomes {#Sec9}
--------------------------------------------------------------

Patients' hemodynamic data, laboratory data, and treatments for septic shock are listed in Table [1](#Tab1){ref-type="table"}. MAP and norepinephrine infusion dose did not differ significantly between the control and PMX-HP groups at T1 and T2. Only one patient in the PMX-HP group required an additional infusion of epinephrine at enrollment, but the infusion was discontinued 4 h after PMX-HP treatment. Total fluid supplementation within the first 48 h did not differ significantly between the PMX-HP and control groups \[6025 (4690--7623) vs. 6034 (5012--7247) mL, *p* = 0.946\]. No significant intergroup differences were noted regarding changes in the SOFA score and APACHE II score from T0 to T2. The total urine output over 48 h after enrollment did not differ significantly between the PMX-HP and control groups \[3615 (2170--5075) vs. 3365 (2373--5078) mL, *p* = 0.946\]. The creatinine level at T1 was nonsignificantly lower in the PMX-HP group than in the control group \[1.1 (0.6) vs. 1.9 (1.5) mg/dL, *p* = 0.110\]. The platelet counts did not differ significantly between the PMX-HP and control groups at T1 and T2 \[T1, 134 (63) vs. 162 (141) k/μL, *p* = 0.504; T2, 122 (47) vs. 127 (83) k/μL, *p* = 0.880\]. PaO~2~/FiO~2~ ratio did not differ significantly between the PMX-HP and control groups \[T0, *n* = 14 vs 14, 244 (125) vs. 265 (147), *p* = 0.689; T1, *n* = 10 vs. 13: 346 (133) vs. 346 (116), *p* = 0.999; T2, *n* = 8 vs. 6: 342 (167) vs. 285 (117), *p* = 0.495\].

Patients' clinical outcomes and survival are presented in Table [2](#Tab2){ref-type="table"}. No significant intergroup differences were noted regarding the ICU stay, hospital stay, and 28-day survival.Table 2Patients' outcomes and survivalGroupControlPMX-HP*p* valuesNumber of patients1414Renal replacement therapy, *n* (%)2 (14%)3 (21%)1.000Ventilator use (days)5 (3--8)5 (3--13)0.571Intensive care unit stay (days)7 (5--12)9 (5--20)0.685Hospital stay (days)22 (15--50)29 (19--51)0.47928-day survival, *n* (%)13 (93%)13 (93%)1.000Data are presented as the number (%) or median (interquartile range)*PMX*-*HP* polymyxin B hemoperfusion

Microcirculation parameters {#Sec10}
---------------------------

A total of 420 video sequences of sublingual microcirculation were recorded for the 28 enrolled patients, and 252 video sequences with appropriate image quality were analyzed according to the description in Methods. Examples of sublingual microcirculation images are presented in Fig. [2](#Fig2){ref-type="fig"}. TVD, PVD, PPV, and MFI of the two groups are presented in Fig. [3](#Fig3){ref-type="fig"}. The intent-to-treat analysis at T1 revealed no significant intergroup differences related to TVD and PVD. At T2, TVD and PVD were higher in the PMX-HP group than in the control group \[TVD 24.2 (22.1--24.9) vs. 21.1 (19.9--22.9) mm/mm^2^; *p* = 0.007; PVD 22.9 (20.9--24.9) vs. 20.0 (18.9--21.6) mm/mm^2^, *p* = 0.008\]. As-treated analysis and per-protocol analysis of TVD and PVD at T1 and T2 are presented in Table [3](#Tab3){ref-type="table"}.Fig. 2Sublingual microcirculation images in patients with sepsis. Time points: T0, at enrollment; T1, at 24--26 h after enrollment; and T2, 48 h after enrollment. *PMX*-*HP* polymyxin B hemoperfusion, *PVD* perfused vessel densityFig. 3Comparison of microcirculation parameters between the control and PMX-HP groups. *n* = 14 patients in each group. Time points: T0, at enrollment; T1, at 24--26 h after enrollment; and T2, 48 h after enrollment. *MFI* microvascular flow index, *PMX*-*HP* polymyxin B hemoperfusion, *PPV* proportion of perfused vessels, *PVD* perfused vessel density, *TVD* total vessel density. \**p* \< 0.05 by intent-to-treat analysis using Mann--Whitney testTable 3Different analyses of total vessel density (TVD) and perfused vessel density (PVD)GroupControlPMX-HP*p* valuesIntent-to-treat analysis Number of patients1414 T1 TVD (mm/mm^2^)20.8 (20.0--24.1)23.3 (20.9--25.2)0.069 T1 PVD (mm/mm^2^)19.7 (18.8--23.2)22.8 (20.9--24.5)0.085T2 TVD21.1 (19.9--22.9)24.2 (22.1--24.9)0.007 T2 PVD20.0 (18.9--21.6)22.9 (20.9--24.9)0.008As-treated analysis Number of patients1315 T1TVD20.5 (19.9--23.4)23.6 (20.9--25.1)0.041 T1 PVD19.3 (18.7--22.5)22.9 (20.9--24.4)0.037 T2 TVD20.7 (19.8--22.7)23.9 (22.1--24.9)0.003 T2 PVD19.8 (18.8--21.0)23.0 (21.3--24.9)0.002Per-protocol analysis Number of patients1314 T1TVD20.5 (19.9--23.4)23.3 (20.9--25.2)0.048 T1 PVD19.3 (18.7--22.5)22.8 (20.9--24.5)0.048 T2 TVD20.7 (19.8--22.7)24.2 (22.1--24.9)0.005 T2 PVD19.8 (18.8--21.0)22.9 (20.9--24.9)0.004Data are presented as median (interquartile range)*PMX*-*HP* polymyxin B hemoperfusion

Discussion {#Sec11}
==========

The question addressed by the present study was whether PMX-HP treatment can improve microcirculation by removing endotoxin and reducing endotoxin-related microcirculatory dysfunction in patients with septic shock. The main finding of this study is that microcirculation in patients with septic shock was improved after PMX-HP treatment. We observed that TVD and PVD were higher in the patients received PMX-HP treatment than in those who received conventional treatment at 48 h after enrollment. However, no significant improvement was observed in the SOFA score, MAP, lactate level, and the total amount of fluid supplementation after PMX-HP treatment.

The finding of improved microcirculation after PMX-HP treatment for septic shock was compatible with the results of the rat sepsis model mentioned in Introduction \[[@CR9]\]. Moreover, our previous septic shock pig study revealed that PMX-HP attenuated microcirculatory dysfunction at the ileal mucosa and kidney surface at 6 h after PMX-HP treatment \[[@CR20]\]. However, no significant improvement was observed regarding sublingual microcirculation at 6 h after PMX-HP treatment in those pigs with septic shock. This observation indicated that different organ exhibited heterogeneity regarding the timing and severity of microcirculatory dysfunction. Compared with PVD in healthy volunteers in our previous study \[[@CR3]\], PVD was 18% (95% confidence interval 10% to 25%) lower at T2 in the control group than in healthy volunteers, and PVD was 7% (95% confidence interval − 1% to 14%) lower, albeit nonsignificantly, at T2 in the PMX-HP group than in healthy volunteers. In addition, the mortality of septic shock in this study was relatively low, and the values of PVD in the two groups were compatible with the values of PVD in survivors with septic shock \[[@CR3]\].

This study did not observe significant intergroup differences in the SOFA score, MAP, and lactate level. The reason for the lack of significant clinical benefits after PMX-HP treatment could be the low severity of septic shock with a relatively low mortality rate of 7% in our enrolled patients. The low mortality rate was compatible with the SOFA score prediction of mortality; an initial score of 9 and a 48-h score of 6 reflect mortality of less than 10% \[[@CR21]\]. Notably, PMX-HP reduced mortality in septic shock patients with intermediate- (30--60%) and high-risks (\> 60%) of mortality \[[@CR22]\]. PMX-HP did not reduce mortality in septic shock patients with a low risk of mortality (\< 30%) \[[@CR22], [@CR23]\]. Therefore, additional studies are required to investigate the effect of PMX-HP on microcirculation in patients with septic shock who have intermediate- and high-risks of mortality.

Our study did not show any adverse effects of PMX-HP treatment. Notably, the incidence of adverse events of PMX-HP treatment has been reported to be very low (\< 1%), and the most commonly observed adverse effects of PMX-HP are thrombocytopenia, transient hypotension, and allergic reactions \[[@CR24]\]. In our study, no significant intergroup difference was observed regarding the platelet count at T1 and T2. Moreover, PMX-HP was reported to remove inflammatory cells \[[@CR25]\], but no significant intergroup difference was noted regarding the white blood cell count at T1 and T2.

Our study has several limitations. First, the study sample size was limited by the strict inclusion and exclusion criteria. Many patients did not meet the inclusion criteria and were excluded based on mild or severe severity of septic shock or a prolonged shock more than 24 h before enrollment. Second, surviving sepsis campaign guidelines have continually improved early resuscitation and survival of patients with septic shock. If patients are recognized early and adequately resuscitated in the emergency department or general ward, they may not need admission to ICUs or require the PMX-HP treatment. Because of the slow progress in recruiting participants after an extended enrollment for more than 4 years, we decided to stop the study before the target sample size was reached. Third, PMX-HP treatment requires heparin loading and infusion to prevent filter clotting, and the dose range of heparin was 1500 to 6000 IU at each session of PMX-HP. According to our heparin dosing protocol \[[@CR15]\], no premature clotting session (\< 90 min) or substantial bleeding event was observed in this study. However, heparin might prevent microthrombosis in small vessels and protect glycocalyx from shedding by suppressing inflammation \[[@CR26]\]. The referenced dose of heparin was 12000 IU/day for 7 days in a randomized trial for the treatment of sepsis \[[@CR27]\]. Hence, additional studies are warranted to investigate the effect of heparin on microcirculation in patients with septic shock. Fourth, the SDF video microscope required an experienced operator to obtain good quality images, and sometimes the enrollment of patients in this study was limited due to unavailability of experienced operators. We suggest that further groups of microcirculation study are encouraged to train their research staff to obtain and analyze the microcirculation images according to the two consensus of assessment of sublingual microcirculation \[[@CR16], [@CR19]\], and communicating with experienced groups of microcirculation study is helpful.

In conclusion, this preliminary study revealed that PMX-HP treatment improved microcirculation but not clinical outcomes in patients with septic shock at a low risk of mortality. Nevertheless, larger multicenter trials are required to confirm the effect of PMX-HP treatment on microcirculation and clinical outcomes in patients with septic shock who have intermediate- and high-risks of mortality.
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